Effects of oral propafenone in patients with frequent ventricular extrasystoles

C. D. Tseng, J. L. Lin, F. T. Chiang, K. L. Hsu, H. M. Lo, Y. Z. Tseng

Research output: Contribution to journalArticle

Abstract

Propafenone is an antiarrhythmic drug with class IC sodium channel blocking agent with mildly β-blocking and calcium channel blocking properties. Oral therapy effectively suppresses supraventricular and ventricular arrhythmias. However, experience with propafenone in Chinese patients is limited. To assess the efficacy and safety of oral propafenone in Chinese patients with frequent ventricular extrasystoles (>20/hour in average) and normal treadmill exercise test and echocardiographic results, 23 patients (14 males and 9 females, mean age 56.5 years) were studied using 24- hour Holter ECG recording. Oral propafenone at a dose of 300 mg/day (12 patients) and 450 mg/day (11 patients) was then given. The 24-hour Holter ECG recording was repeated 4 weeks later to evaluate the suppressive effect of propafenone. Blood pressure and adverse effects were also recorded at each visit. When all patients taking 300 mg/day were analyzed as a group, no stastistically significant suppresion of ventricular extrasystoles was noted, whereas patients taking 450 mg/day had significant suppression of total ventricular ectopies, isolated ventricular ectopies, and average ventricular ectopies. Therapeutic success (>85% suppression of ventricular ectop) was achieved in 41.7% (5/12) of in those taking 300 mg/day and in 63.6% (7/11) of those taking 450 mg/day. Of the three patients taking 450 mg/day, who did not achieve >85% suppression, two patients showed significant suppression of ventricular ectopies without adverse effects when the dose was increased to 600 mg/day. During the treatment period, no patient reported arrhythmia- related ill effects or developed hemodynamic instability, although three patients had transient and asymptomatic bradycardia during the 24-hour Holter ECG recording. Therefore, we conclude that oral propafenone is effective at a dose range of 300 to 600 mg/day is effective and safe in the suppression of frequent ventricular extrasystoles in patients with functionally normal heart.

Original languageEnglish
Pages (from-to)259-264
Number of pages6
JournalTzu Chi Medical Journal
Volume9
Issue number4
Publication statusPublished - Dec 1 1997
Externally publishedYes

Fingerprint

Propafenone
Ventricular Premature Complexes
Electrocardiography
Exercise Test
Cardiac Arrhythmias
Sodium Channels
Anti-Arrhythmia Agents
Calcium Channels
Bradycardia

Keywords

  • Holter monitoring
  • Propafenone
  • Ventricular ectopies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tseng, C. D., Lin, J. L., Chiang, F. T., Hsu, K. L., Lo, H. M., & Tseng, Y. Z. (1997). Effects of oral propafenone in patients with frequent ventricular extrasystoles. Tzu Chi Medical Journal, 9(4), 259-264.

Effects of oral propafenone in patients with frequent ventricular extrasystoles. / Tseng, C. D.; Lin, J. L.; Chiang, F. T.; Hsu, K. L.; Lo, H. M.; Tseng, Y. Z.

In: Tzu Chi Medical Journal, Vol. 9, No. 4, 01.12.1997, p. 259-264.

Research output: Contribution to journalArticle

Tseng, CD, Lin, JL, Chiang, FT, Hsu, KL, Lo, HM & Tseng, YZ 1997, 'Effects of oral propafenone in patients with frequent ventricular extrasystoles', Tzu Chi Medical Journal, vol. 9, no. 4, pp. 259-264.
Tseng CD, Lin JL, Chiang FT, Hsu KL, Lo HM, Tseng YZ. Effects of oral propafenone in patients with frequent ventricular extrasystoles. Tzu Chi Medical Journal. 1997 Dec 1;9(4):259-264.
Tseng, C. D. ; Lin, J. L. ; Chiang, F. T. ; Hsu, K. L. ; Lo, H. M. ; Tseng, Y. Z. / Effects of oral propafenone in patients with frequent ventricular extrasystoles. In: Tzu Chi Medical Journal. 1997 ; Vol. 9, No. 4. pp. 259-264.
@article{133f1ca5f7794f56a3986df145eb00d5,
title = "Effects of oral propafenone in patients with frequent ventricular extrasystoles",
abstract = "Propafenone is an antiarrhythmic drug with class IC sodium channel blocking agent with mildly β-blocking and calcium channel blocking properties. Oral therapy effectively suppresses supraventricular and ventricular arrhythmias. However, experience with propafenone in Chinese patients is limited. To assess the efficacy and safety of oral propafenone in Chinese patients with frequent ventricular extrasystoles (>20/hour in average) and normal treadmill exercise test and echocardiographic results, 23 patients (14 males and 9 females, mean age 56.5 years) were studied using 24- hour Holter ECG recording. Oral propafenone at a dose of 300 mg/day (12 patients) and 450 mg/day (11 patients) was then given. The 24-hour Holter ECG recording was repeated 4 weeks later to evaluate the suppressive effect of propafenone. Blood pressure and adverse effects were also recorded at each visit. When all patients taking 300 mg/day were analyzed as a group, no stastistically significant suppresion of ventricular extrasystoles was noted, whereas patients taking 450 mg/day had significant suppression of total ventricular ectopies, isolated ventricular ectopies, and average ventricular ectopies. Therapeutic success (>85{\%} suppression of ventricular ectop) was achieved in 41.7{\%} (5/12) of in those taking 300 mg/day and in 63.6{\%} (7/11) of those taking 450 mg/day. Of the three patients taking 450 mg/day, who did not achieve >85{\%} suppression, two patients showed significant suppression of ventricular ectopies without adverse effects when the dose was increased to 600 mg/day. During the treatment period, no patient reported arrhythmia- related ill effects or developed hemodynamic instability, although three patients had transient and asymptomatic bradycardia during the 24-hour Holter ECG recording. Therefore, we conclude that oral propafenone is effective at a dose range of 300 to 600 mg/day is effective and safe in the suppression of frequent ventricular extrasystoles in patients with functionally normal heart.",
keywords = "Holter monitoring, Propafenone, Ventricular ectopies",
author = "Tseng, {C. D.} and Lin, {J. L.} and Chiang, {F. T.} and Hsu, {K. L.} and Lo, {H. M.} and Tseng, {Y. Z.}",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "9",
pages = "259--264",
journal = "Tzu Chi Medical Journal",
issn = "1016-3190",
publisher = "財團法人中華民國佛教慈濟慈善事業基金會",
number = "4",

}

TY - JOUR

T1 - Effects of oral propafenone in patients with frequent ventricular extrasystoles

AU - Tseng, C. D.

AU - Lin, J. L.

AU - Chiang, F. T.

AU - Hsu, K. L.

AU - Lo, H. M.

AU - Tseng, Y. Z.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Propafenone is an antiarrhythmic drug with class IC sodium channel blocking agent with mildly β-blocking and calcium channel blocking properties. Oral therapy effectively suppresses supraventricular and ventricular arrhythmias. However, experience with propafenone in Chinese patients is limited. To assess the efficacy and safety of oral propafenone in Chinese patients with frequent ventricular extrasystoles (>20/hour in average) and normal treadmill exercise test and echocardiographic results, 23 patients (14 males and 9 females, mean age 56.5 years) were studied using 24- hour Holter ECG recording. Oral propafenone at a dose of 300 mg/day (12 patients) and 450 mg/day (11 patients) was then given. The 24-hour Holter ECG recording was repeated 4 weeks later to evaluate the suppressive effect of propafenone. Blood pressure and adverse effects were also recorded at each visit. When all patients taking 300 mg/day were analyzed as a group, no stastistically significant suppresion of ventricular extrasystoles was noted, whereas patients taking 450 mg/day had significant suppression of total ventricular ectopies, isolated ventricular ectopies, and average ventricular ectopies. Therapeutic success (>85% suppression of ventricular ectop) was achieved in 41.7% (5/12) of in those taking 300 mg/day and in 63.6% (7/11) of those taking 450 mg/day. Of the three patients taking 450 mg/day, who did not achieve >85% suppression, two patients showed significant suppression of ventricular ectopies without adverse effects when the dose was increased to 600 mg/day. During the treatment period, no patient reported arrhythmia- related ill effects or developed hemodynamic instability, although three patients had transient and asymptomatic bradycardia during the 24-hour Holter ECG recording. Therefore, we conclude that oral propafenone is effective at a dose range of 300 to 600 mg/day is effective and safe in the suppression of frequent ventricular extrasystoles in patients with functionally normal heart.

AB - Propafenone is an antiarrhythmic drug with class IC sodium channel blocking agent with mildly β-blocking and calcium channel blocking properties. Oral therapy effectively suppresses supraventricular and ventricular arrhythmias. However, experience with propafenone in Chinese patients is limited. To assess the efficacy and safety of oral propafenone in Chinese patients with frequent ventricular extrasystoles (>20/hour in average) and normal treadmill exercise test and echocardiographic results, 23 patients (14 males and 9 females, mean age 56.5 years) were studied using 24- hour Holter ECG recording. Oral propafenone at a dose of 300 mg/day (12 patients) and 450 mg/day (11 patients) was then given. The 24-hour Holter ECG recording was repeated 4 weeks later to evaluate the suppressive effect of propafenone. Blood pressure and adverse effects were also recorded at each visit. When all patients taking 300 mg/day were analyzed as a group, no stastistically significant suppresion of ventricular extrasystoles was noted, whereas patients taking 450 mg/day had significant suppression of total ventricular ectopies, isolated ventricular ectopies, and average ventricular ectopies. Therapeutic success (>85% suppression of ventricular ectop) was achieved in 41.7% (5/12) of in those taking 300 mg/day and in 63.6% (7/11) of those taking 450 mg/day. Of the three patients taking 450 mg/day, who did not achieve >85% suppression, two patients showed significant suppression of ventricular ectopies without adverse effects when the dose was increased to 600 mg/day. During the treatment period, no patient reported arrhythmia- related ill effects or developed hemodynamic instability, although three patients had transient and asymptomatic bradycardia during the 24-hour Holter ECG recording. Therefore, we conclude that oral propafenone is effective at a dose range of 300 to 600 mg/day is effective and safe in the suppression of frequent ventricular extrasystoles in patients with functionally normal heart.

KW - Holter monitoring

KW - Propafenone

KW - Ventricular ectopies

UR - http://www.scopus.com/inward/record.url?scp=0031467031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031467031&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031467031

VL - 9

SP - 259

EP - 264

JO - Tzu Chi Medical Journal

JF - Tzu Chi Medical Journal

SN - 1016-3190

IS - 4

ER -